39
Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D.

Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Embed Size (px)

Citation preview

Page 1: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Clinical Pharmacology

Autonomic pharmacology

Jane M Johnston Ph.D.

Page 2: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Efferent (motor) nerves Two systems

Autonomic nerves (unconscious) Eg cardiac output, respiration, etc

Somatic nerves (voluntary)

Page 3: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

ANS branches cholinergic fibres - acetylcholine adrenergic fibres noradrenaline (norepinepherine

NE)

Page 4: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Functions and origins of the ANS

Page 5: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Action of ANS drugs

Drugs to block ANS chemical transmission

Drugs to mimic ANS action ANS drugs can modify a variety of

effector tissues Cardiac muscle Blood pressure Exocrine glands

Page 6: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Cholinergic transmission

Acetylcholine is at motor neuron and CNS nerve terminals

Synthesized from Acetyl coA (mitochondria) Choline (dietary) Catalyzed by choline acetyl transferase (ChAT)

Release is dependent on Calcium (Ca2+) Causes muscle contraction

Page 7: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Acetylcholine

Identified 1921 Present at all NMJ and also CNS Synthesized in the axon terminal Diffuses across synaptic cleft Two receptor subtypes

Nicotinic ACh receptors Muscarinic ACh receptors

Page 8: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

The discovery of vagusstoff

E.Chudler 2001

Page 9: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Neuromuscular Junction

Synaptic End Plate

T.Caceri Veterinary Histology 2003

1999 Sinauer Associates Inc

Page 10: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Acetylcholine and NMJ

Page 11: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Characteristics of a neurotransmitter

Synthesized in (or transported to) presynaptic terminal

Stored in vesicles Regulated release Receptor located on postsynaptic

membrane Termination of action

Page 12: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Synaptic vesicles at the NMJ (EM)

Heuser and Heuser

Page 13: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Synthesis and release of neurotransmitters

Synaptic Transmission in: Basic Neurochemistry 6 th Edition

Page 14: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Presynaptic events

Calcium influx releases synaptic vesicles from microtubules

Movement of synaptic vesicles to sites of action

Interaction of specific proteins Vesicle docking Membrane fusion Calcium dependent exocytosis

Page 15: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Fusion proteins regulate neurotransmitter release

Vesicle proteins Synaptobrevin

Presynaptic membrane proteins Syntaxins SNAP-25

Page 16: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

The SNARE hypothesis

SNARE (Soluble N’ethylmalemide sensitive fusion Attachment protein REceptor)

A. Pestronk www.neuro.wustl.edu/neuromuscular 2003

Page 17: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Many presynaptic proteins regulate neurotransmitter release

Synaptic Transmission in: Basic Neurochemistry 6 th Edition

Page 18: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Vesicular transport of NT – drug implications

Toxins targeting neurotransmitter release Spider venom (excess ACh release) Botulinum (blocks ACh release)

Tetanus

Page 19: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Postsynaptic events

Boutons have multiple nerve terminals Simultaneous release Stimulation of contraction via AP Acetylcholine degraded after action

ACETYLCHOLINESTERASE (AChE)

Page 20: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Motor neuron innervating skeletal muscle

Page 21: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Cholinergic receptors

Two classes for acetylcholine Nicotinic and muscarinic

Nicotinic are ion channels

Ionotrophic Muscarinic are G-protein coupled

Metabotrophic

Page 22: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Nicotinic AChR are sodium channels

1999 Sinauer Associates Inc

Page 23: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Ionotropic AChR

Consist of five polypeptide subunits

Receptors vary in: subunit structure agonist sensitivity distribution

Mediate fast synaptic transmission

Page 24: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Muscarinic AChR activate G-proteins

1999 Sinauer Associates Inc

Page 25: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Metabotropic AChR

Five muscarinic AChR subtypes G protein coupled Slower synaptic transmission

via intracellular signaling cascade

Page 26: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Mode of cholinergic drug action

Cholinomimetics agonist antagonist

Cholinesterase inhibitors Clinical applications

Page 27: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Cholinomimetics

Katzung, 2001

Page 28: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

AChR agonists and antagonists Nicotinic AChR agonists

Nicotine Nicotinic AChR antagonists

Strychnine Snake toxins Bungarotoxin

Muscarinic AChR agonist Muscarine

Muscarinic AChR antagonists Atropine

Page 29: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Cholinesterase inhibitors

Inhibit breakdown of acetylcholine at the synapse

Act by Binding to acetylcholine esterase (steric

hinderance or hydrolysis) Actions of acetylcholine persist at synapse

Pesticides and nerve gases

Page 30: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Clinical Implications

Myasthenia Gravis Glaucoma Cholinergic poisons CNS –

Alzheimer’s Disease Schizophrenia

Page 31: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Myasthenia gravis

Affects skeletal muscle at NMJ Involves autoimmunity to nicotinic

receptors Extreme weakness, difficulty

speaking, eating, breathing Cholinesterase inhibitors for therapy

Page 32: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Adrenergic transmission Catecholamines are the neuroTs Complex synthesis Secretion at nerve terminals and adrenal glands Adrenal glands

Two adrenal glands Consist of cortex (outer) medulla (inner)

medulla secretes: Epinephrine (adrenaline) Norepinephrine

Page 33: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

NE and E are released at nerve terminals and secreted by the adrenal medulla

Page 34: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Norepinephrine and epinephrine

Catecholamines Synthesized from dopamine Present in CNS and sympathetic

nerves Widely distributed, general

behavioral arousal eg raise blood pressure etc

Stress increases release of norepinephrine

Page 35: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Synthesis of norepinephrine (NA)

Page 36: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Synthesis of epinephrine (adrenaline)

Page 37: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Adrenergic receptors

Four receptor subtypes 1, 2, 1, 2

G protein linked Bind either norepinephrine or epinephrine

Page 38: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Sympathetomimetic drugs Can act directly or indirectly Direct binding to receptors

Epinepherine, dopamine (CNS and renal)

Indirectly Drugs targeting synthesis and release of NE and

NA eg DBH inhibitors, reserpine - depletes stores Drugs targeting reuptake at synapse eg cocaine,

Tricyclic antidepressants

Page 39: Clinical Pharmacology Autonomic pharmacology Jane M Johnston Ph.D

Importance of sympathetomimetic drugs

Cardiovascular system Regulation of smooth muscle affects heart and blood

pressure beta blockers

Respiratory tract Smooth muscle relaxation – bronchodilation

Isoproterenol, albuterol (asthma)

Metabolic effects Liver effects, insulin secretion

CNS Nervousness, emotional well-being, psychosis etc